BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX), a biopharmaceutical company focused on oncology, has revealed preclinical data at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, suggesting that its two proprietary antibodies, CTX-009 and CTX-471, could be effective against tumors that are resistant to current immune-oncology therapies.
The data presented indicates that the combination of CTX-009, a bispecific antibody targeting DLL4 and VEGF pathways, and CTX-471, an agonistic anti-CD137 antibody, showed enhanced anti-tumor activity in models of both checkpoint inhibitor-sensitive and resistant tumors.
This is particularly significant for tumors that are negative for Major Histocompatibility Complex Class I (MHC-I), which typically evade the immune system's CD8+ T-Cells.
The study's results demonstrated that the combination therapy could potentially re-establish anti-tumor immunity in patients with MHC-I negative tumors through NK-cell mediated tumor cell killing. This suggests a new therapeutic strategy for patients who have not responded to checkpoint inhibitors like anti-PD-1 and anti-PD-L1 antibodies.
Compass Therapeutics has indicated that CTX-009 has already shown partial responses as a monotherapy in heavily pre-treated patients with cancer who were resistant to approved anti-VEGF therapies. CTX-471 is currently being evaluated in a Phase 1b clinical trial in patients with solid tumors that have progressed after treatment with approved PD-1 or PD-L1 inhibitors.
The company, based in Boston, Massachusetts, aims to advance these product candidates through clinical development, with the potential to offer new treatment options for patients with significant unmet medical needs in oncology.
The information presented in this article is based on a press release statement from Compass Therapeutics.
InvestingPro Insights
As Compass Therapeutics, Inc. (NASDAQ:CMPX) continues to make strides in developing novel oncology treatments, investors may be curious about the company's financial health and market performance. According to InvestingPro data, CMPX has a market capitalization of $233.9 million. Despite the potential of their therapies, the company's P/E ratio stands at -6.37, reflecting the market's current skepticism about future earnings.
InvestingPro Tips suggest that while Compass Therapeutics holds more cash than debt on its balance sheet, it is quickly burning through cash and has been suffering from weak gross profit margins. Mor, the company is not expected to be profitable this year, and analysts do not anticipate a turnaround in the near term, as the company has not been profitable over the last twelve months and does not pay a dividend to shareholders.
These factors are essential considerations for investors looking at the long-term viability of Compass Therapeutics.
Investors interested in a deeper dive into Compass Therapeutics' financials and future prospects can find additional insights on InvestingPro, where there are more InvestingPro Tips available. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to comprehensive analysis tools and real-time data to inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.